These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

893 related items for PubMed ID: 10675220

  • 1. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
    Ferner RE, Lucas JD, O'Doherty MJ, Hughes RA, Smith MA, Cronin BF, Bingham J.
    J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
    [Abstract] [Full Text] [Related]

  • 2. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
    Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V, O'Doherty M.
    Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
    [Abstract] [Full Text] [Related]

  • 3. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
    Karabatsou K, Kiehl TR, Wilson DM, Hendler A, Guha A.
    Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
    [Abstract] [Full Text] [Related]

  • 4. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.
    Tsai LL, Drubach L, Fahey F, Irons M, Voss S, Ullrich NJ.
    J Neurooncol; 2012 Jul; 108(3):469-75. PubMed ID: 22407214
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours.
    Cardona S, Schwarzbach M, Hinz U, Dimitrakopoulou-Strauss A, Attigah N, Mechtersheimer section sign G, Lehnert T.
    Eur J Surg Oncol; 2003 Aug; 29(6):536-41. PubMed ID: 12875862
    [Abstract] [Full Text] [Related]

  • 6. Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of 18F-FDG PET.
    Cook GJR, Lovat E, Siddique M, Goh V, Ferner R, Warbey VS.
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1845-1852. PubMed ID: 28589254
    [Abstract] [Full Text] [Related]

  • 7. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).
    Meany H, Dombi E, Reynolds J, Whatley M, Kurwa A, Tsokos M, Salzer W, Gillespie A, Baldwin A, Derdak J, Widemann B.
    Pediatr Blood Cancer; 2013 Jan; 60(1):59-64. PubMed ID: 22645095
    [Abstract] [Full Text] [Related]

  • 8. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.
    Warbey VS, Ferner RE, Dunn JT, Calonje E, O'Doherty MJ.
    Eur J Nucl Med Mol Imaging; 2009 May; 36(5):751-7. PubMed ID: 19142634
    [Abstract] [Full Text] [Related]

  • 9. Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [18 F]FDG-PET imaging. Is it of value in asymptomatic patients?
    Azizi AA, Slavc I, Theisen BE, Rausch I, Weber M, Happak W, Aszmann O, Hojreh A, Peyrl A, Amann G, Benkoe TM, Wadsak W, Kasprian G, Staudenherz A, Hacker M, Traub-Weidinger T.
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28771999
    [Abstract] [Full Text] [Related]

  • 10. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A, Chaudhry M, Blakeley JO, Wahl R.
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [Abstract] [Full Text] [Related]

  • 11. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.
    Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA, Eilber FC.
    Cancer; 2010 Jan 15; 116(2):451-8. PubMed ID: 19924789
    [Abstract] [Full Text] [Related]

  • 12. False-negative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of neurofibromatosis type 1.
    Shahid KR, Amrami KK, Esther RJ, Lowe VJ, Spinner RJ.
    J Surg Orthop Adv; 2011 Jan 15; 20(2):132-5. PubMed ID: 21838076
    [Abstract] [Full Text] [Related]

  • 13. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.
    Salamon J, Veldhoen S, Apostolova I, Bannas P, Yamamura J, Herrmann J, Friedrich RE, Adam G, Mautner VF, Derlin T.
    Eur Radiol; 2014 Feb 15; 24(2):405-12. PubMed ID: 24097302
    [Abstract] [Full Text] [Related]

  • 14. Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.
    Salamon J, Mautner VF, Adam G, Derlin T.
    Rofo; 2015 Dec 15; 187(12):1084-92. PubMed ID: 26333104
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1.
    Salamon J, Derlin T, Bannas P, Busch JD, Herrmann J, Bockhorn M, Hagel C, Friedrich RE, Adam G, Mautner VF.
    Eur J Nucl Med Mol Imaging; 2013 May 15; 40(5):685-92. PubMed ID: 23232507
    [Abstract] [Full Text] [Related]

  • 16. Association between benign and malignant peripheral nerve sheath tumors in NF1.
    Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM.
    Neurology; 2005 Jul 26; 65(2):205-11. PubMed ID: 16043787
    [Abstract] [Full Text] [Related]

  • 17. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.
    Urban T, Lim R, Merker VL, Muzikansky A, Harris GJ, Kassarjian A, Bredella MA, Plotkin SR.
    Clin Nucl Med; 2014 May 26; 39(5):e301-7. PubMed ID: 24152623
    [Abstract] [Full Text] [Related]

  • 18. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas.
    Tucker T, Friedman JM, Friedrich RE, Wenzel R, Fünsterer C, Mautner VF.
    J Med Genet; 2009 Feb 26; 46(2):81-5. PubMed ID: 18930997
    [Abstract] [Full Text] [Related]

  • 19. Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.
    Uthoff J, De Stefano FA, Panzer K, Darbro BW, Sato TS, Khanna R, Quelle DE, Meyerholz DK, Weimer J, Sieren JC.
    J Neuroradiol; 2019 May 26; 46(3):179-185. PubMed ID: 29958847
    [Abstract] [Full Text] [Related]

  • 20. The Role of [18F]FDG-PET/CT in Predicting Malignant Transformation of Plexiform Neurofibromas in Neurofibromatosis-1.
    Tovmassian D, Abdul Razak M, London K.
    Int J Surg Oncol; 2016 May 26; 2016():6162182. PubMed ID: 28058117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.